• POD12- BENIGN PROSTATIC HYPERPLASIA- RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE

    Sep 1, 2001, 00:00

  • DB1- ESTIMATING HEALTH-CARE COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS USING DATA FROM THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS)

    Sep 1, 2001, 00:00

  • PMH8- SCHIZOPHRENIA OUTCOMES RESEARCH STUDY IN SPAIN- TOLERABILITY AND ECONOMIC RESULTS WITH ATYPICAL ANTIPSYCHOTICS

    Sep 1, 2001, 00:00

  • RS1- OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA- A COMPARISON OF SYMPTOM-FREE TIME AND MULTI-ATTRIBUTE SCALE

    Sep 1, 2001, 00:00

  • CN2- EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT

    Sep 1, 2001, 00:00

  • PAM4- USE OF COX 2 NSAIDS IN SUBJECTS WITHOUT RISK OF GASTROINTESTINAL SIDE EFFECTS

    Sep 1, 2001, 00:00

  • PMH5- THE COST-EFFECTIVENESS OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS PARTIALLY RESPONSIVE TO PREVIOUS ANTIPSYCHOTICS-AN ECONOMIC ANALYSIS OF THE PRIZE STUDY

    Sep 1, 2001, 00:00

  • PPN3- THE IMPACT OF DEMENTIA ON CAREGIVER QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • PMH16- ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA- ADVERSE EVENTS, NON-COMPLIANCE AND COST

    Sep 1, 2001, 00:00

  • PCV30- A POPULATION-BASED EUROPEAN STUDY OF PERSISTENCE IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS

    Sep 1, 2001, 00:00

  • HP3- REGIONAL VARIATION IN PRESCRIPTION USE IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PPN20- ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS- RESULTS FROM THE MIMS TRIAL

    Sep 1, 2001, 00:00

  • PDG24- PHARMACOECONOMIC ASSESSMENT OF RABEPRAZOLE IN PEPTIC ULCER IN RUSSIA

    Sep 1, 2001, 00:00

  • PAR15- COMPARISON OF HEALTH CARE RESOURCE UTILIZATION OF COPD PATIENTS ON CILOMILAST, 15 MG BID VERSUS PLACEBO

    Sep 1, 2001, 00:00

  • PCN19- CHOICE OF OPTIMAL ANTI-EMETIC STRATEGIES IN CANCER THERAPY

    Sep 1, 2001, 00:00

  • PGI15- COMPUTERIZED ASSESSMENT OF COMPLICATIONS FOLLOWING COLORECTAL SURGERY

    Sep 1, 2001, 00:00

  • PDB11- ECONOMIC OUTCOMES OF DIABETES AMONG AN EMPLOYED POPULATION

    Sep 1, 2001, 00:00

  • PCV34- STOP SMOKING CESSATION TARGET- OBSERVATION PROGRAM, THE FRENCH PHARMACISTS PROGRESS

    Sep 1, 2001, 00:00

  • PCV33- IMPACT OF INSURANCE TYPES ON PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION- DIURETICS OR BETA-BLOCKERS VS. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR CALCIUM CHANNEL BLOCKERS

    Sep 1, 2001, 00:00

  • PEE10- IS NON-CONTACT NORMOTHERMIC WOUND THERAPY COST-EFFECTIVE FOR THE TREATMENT OF STAGE 3 AND 4 PRESSURE ULCERS?

    Sep 1, 2001, 00:00

  • PMA7- CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING

    Sep 1, 2001, 00:00

  • PDB4- COST-EFFECTIVENESS AND CARDIOVASCULAR RISK-AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

    Sep 1, 2001, 00:00

  • MD2- ANALYSIS OF THE IMPACT OF ASSISTIVE LIVING DEVICES ON SELF-ASSESSED HEALTH STATUS RATING

    Sep 1, 2001, 00:00

  • PIN14- A STUDY ON THE HEALTH EFFECTS OF FLU AND FLU-LIKE ILLNESSES IN THE WORKING POPULATION AND THEIR COST IMPACT ON A BIG CORPORATION IN HONG KONG

    Sep 1, 2001, 00:00

  • PCN14- CHOICE OF LOCALIZED BREAST CANCER TREATMENTS IN A MEDICARE POPULATION- A COMPARISON OF OUTCOMES AND COSTS

    Sep 1, 2001, 00:00

  • PND6- ASSESSING THE COSTS OF PARKINSONS DISEASE IN GERMANY

    Sep 1, 2001, 00:00

  • PPN19- COMPARISON OF HUI2 AND HUI3 SCORES FOR PATIENTS WITH ALZHEIMERS DISEASE

    Sep 1, 2001, 00:00

  • WW12- USE OF MEDICATION COMPLIANCE DATA IN OUTCOME ANALYSES

    Sep 1, 2001, 00:00

  • PMA17- THE EUROPEAN SERVICE MAPPING SCHEDULE (ESMS)- A NEW INSTRUMENT FOR MENTAL HEALTH SERVICES RESEARCH, RESULTS OF A FRENCH STUDY

    Sep 1, 2001, 00:00

  • PID27- DOES A DAY STILL MAKE A DIFFERENCE? A DECISION ANALYSIS OF ADULT STREPTOCOCCAL PHARYNGITIS

    Sep 1, 2001, 00:00

  • MH2- FUTURE EMPLOYABILITY- A NEW APPROACH TO COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTIC THERAPY

    Sep 1, 2001, 00:00

  • PMH17- LONG-TERM ECONOMIC BENEFITS OF ANTIPSYCHOTIC USE

    Sep 1, 2001, 00:00

  • PGI2- ALTERNATIVE MANAGEMENT STRATEGIES FOR DYSPEPSIA

    Sep 1, 2001, 00:00

  • HP6- THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS

    Sep 1, 2001, 00:00

  • CH2- TRANSITION IN HEALTH-RELATED QUALITY OF LIFE IN U.S. ELDERLY

    Sep 1, 2001, 00:00

  • PCV40- COST-EFFECTIVENESS OF LIPID LOWERING INTERVENTIONS IN A NATIVE AMERICAN CARDIOVASCULAR RISK REDUCTION PROGRAM

    Sep 1, 2001, 00:00

  • PDB14- IMPACT OF A DIABETES DISEASE MANAGEMENT PROGRAM- A RETROSPECTIVE CLAIMS-BASED EVALUATION

    Sep 1, 2001, 00:00

  • PHP10- THE ROAD TO JAPAN/KOREA 2002- PROSPECTS FOR JAPANESE PHARMACOECONOMICS

    Sep 1, 2001, 00:00

  • PMA1- METHODOLOGICAL ADVANCES IN THE ASSESSMENT OF QUALITY OF LIFE IN CLINICAL TRIALS

    Sep 1, 2001, 00:00

  • PAR20- EFFECTIVENESS OF COMPLIANCE ON HEALTH CARE RESOURCE USE IN ASTHMA PATIENTS TREATED WITH MONTELUKAST VS. INHALED CORTICOSTEROIDS

    Sep 1, 2001, 00:00

  • PCV35- COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY- DO THE RESULTS HELP THE DECISION-MAKING PROCESS?

    Sep 1, 2001, 00:00

  • PCV21- COST-EFFECTIVENESS ANALYSIS OF ABCIXIMAB, EPTIFIBATIDE, AND TIROFIBAN IN PATIENTS WITH CORONARY SYNDROMES

    Sep 1, 2001, 00:00

  • PEE5- COSTS AND CONSEQUENCES OF LASIK, GLASSES AND CONTACT LENSES IN MILD TO MODERATE MYOPIA-A SPANISH SOCIETAL APPROACH

    Sep 1, 2001, 00:00

  • PAO12- DIRECT MEDICAL COST OF OSTEOPOROSIS IN THE UNITED STATES- PROJECTIONS FOR 2000-2025

    Sep 1, 2001, 00:00

  • PMI14- TO TRANSLATE OR TO ADAPT-WHAT DO THE QUESTIONS MEAN?

    Sep 1, 2001, 00:00

  • PIN9- COST-BENEFIT ANALYSIS OF VACCINATING HEALTHY WORKING ADULTS AGAINST INFLUENZA IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCV22- IN-PATIENT AND OUT-PATIENT RESOURCE UTILIZATION AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE-THE VA EXPERIENCE

    Sep 1, 2001, 00:00

  • PND1- ASSOCIATION OF FAMILY HARDINESS WITH WORK PRODUCTIVITY AND ACTIVITY IN FAMILIES OF PEDIATRIC PATIENTS WITH EPILEPSY

    Sep 1, 2001, 00:00

  • PCV16- COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME PATIENTS IN POLAND

    Sep 1, 2001, 00:00

  • PPN21- MIGRAINE IN FRANCE IN 2000-THERAPEUTICAL DATA

    Sep 1, 2001, 00:00

  • PHP23- HOSPITAL READMISSIONS OF OLDER PEOPLE

    Sep 1, 2001, 00:00

  • QL1- DOES SOCIOECONOMIC STATUS AFFECT THE VALUATION OF HEALTH?

    Sep 1, 2001, 00:00

  • PHP16- HOW RESPONSIVE ARE OUR HEALTH CENTRES?

    Sep 1, 2001, 00:00

  • PCN5- DOCETAXEL/DOXORRUBICIN (DD) AS FIRST LINE CHEMOTHERAPY- QUALITY OF LIFE (QOL) IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC)

    Sep 1, 2001, 00:00

  • PAM2- AN ECONOMIC EVALUATION OF OSTEOPOROSIS MEDICATION USE PATTERNS IN A MANAGED CARE ORGANIZATION- A TIME TO FRACTURE ANALYSIS

    Sep 1, 2001, 00:00

  • PEE8- FOUR YEAR COST-EFFECTIVENESS OF INITIAL TRABECULECTOMY VERSUS CONVENTIONAL THERAPY IN PRIMARY OPEN-ANGLE GLAUCOMA (POAG)

    Sep 1, 2001, 00:00

  • PAO9- DISABILITY, RESOURCE UTILISATION, AND WORK ABSENCES ASSOCIATED WITH OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA)- AN INTERNATIONAL DATABASE ANALYSIS

    Sep 1, 2001, 00:00

  • RS3- PSYCHOMETRIC EVALUATION OF THE CAP-SYM QUESTIONNAIRE- A NEW, PATIENT-BASED MEASURE OF SYMPTOMS IN COMMUNITY ACQUIRED PNEUMONIA

    Sep 1, 2001, 00:00

  • PDB12- A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE

    Sep 1, 2001, 00:00

  • PPN16- ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE DUE TO LOW BACK PAIN

    Sep 1, 2001, 00:00

  • PCV15- CHRONIC VENOUS INSUFFICENCY (CVI) IN POLAND-A COST OF ILLNESS STUDY

    Sep 1, 2001, 00:00

  • Modeling for Health Care and Other Policy Decisions- Uses, Roles, and Validity

    Sep 1, 2001, 00:00

  • PCV1- A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN AS PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH ESTABLISHED PERIPHERAL ARTERY DISEASE

    Sep 1, 2001, 00:00

  • PCN16- ELAPSED TIME TO DISCLOSURE OF BRCAI/2 GENETIC TESTING RESULTS AND PARTICIPANTS DISTRESS- PRELIMINARY FINDINGS FROM A RESEARCH SETTING

    Sep 1, 2001, 00:00

  • PMH4- ASSESSMENT OF PATIENTS ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL

    Sep 1, 2001, 00:00

  • EM1- RISK ATTITUDE- ASSOCIATION WITH MAGNITUDE OF RISK AND PATIENT CHARACTERISTICS

    Sep 1, 2001, 00:00

  • CV8- WORK-RELATED OUTCOMES OF PATIENTS SIX MONTHS AFTER MYOCARDIAL INFARCTION

    Sep 1, 2001, 00:00

  • PCV12- QUALITY OF CARE IN OLDER PATIENTS ADMITTED TO HOSPITAL WITH HEART FAILURE

    Sep 1, 2001, 00:00

  • PAO14- THE COST-EFFECTIVENESS OF CALCIUM AND VITAMIN D3 SUPPLEMENTATION FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURES IN SWEDEN

    Sep 1, 2001, 00:00

  • WW2- USING LINKABLE CLINICAL AND ADMINISTRATIVE CLAIMS DATA TO IMPROVE OUTCOMES RESEARCH- SELECTED CASE STUDIES FROM ONCOLOGY AND DIABETES MELLITUS

    Sep 1, 2001, 00:00

  • PDG17- AN ECONOMIC ANALYSIS OF IRBESARTAN IN TYPE II DIABETIC NEPHROPATHY

    Sep 1, 2001, 00:00

  • PEE7- THE BURDEN OF AGE-RELATED MACULAR DEGENERATION-RESULTS OF A COHORT STUDY IN TWO FRENCH REFERRAL CARE CENTERS

    Sep 1, 2001, 00:00

  • PRP8- LIFETIME COSTS OF COPD IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PHP3- PHARMACOECONOMIC FELLOWSHIPS- STRUCTURE, PROCESS, AND OUTCOMES

    Sep 1, 2001, 00:00

  • PGI12- ESTIMATING POTENTIAL UTILIZATION OF ESOMEPRAZOLE BY ASSESSING GERD SYMPTOM CONTROL ON TRADITIONAL PPIS

    Sep 1, 2001, 00:00

  • PCN8- ECONOMIC EVALUATION OF GEMZAR IN THE TREATMENT OF PANCREATIC CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PMH30- DIFFERENCES IN HEALTH CARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY

    Sep 1, 2001, 00:00

  • PID3- TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PAO1- THERAPEUTIC COMPARABILITY OF COX-2 INHIBITORS

    Sep 1, 2001, 00:00

  • PMH16- USE OF RASCH MODELS FOR VALIDATION OF INSTRUMENTS USED IN MENTAL HEALTH EVALUATION

    Sep 1, 2001, 00:00

  • PID12- AVERTING FUTURE AIDS CASES- MODELING COSTS OF INTERVENTIONS WITH OUT-OF-TREATMENT SUBSTANCE ABUSERS

    Sep 1, 2001, 00:00

  • PAM5- INVESTIGATING THE CONSTRUCT VALIDITY OF A DISEASE SPECIFIC AND A GENERAL QUALITY OF LIFE INSTRUMENTS OF PATIENTS WITH RHEUMATOID ARTHRITIS

    Sep 1, 2001, 00:00

  • PQP8- EVALUATING BIAS INTRODUCED BY ANNUALIZING UTILIZATION AND COST MEASURES

    Sep 1, 2001, 00:00

  • PQP4- CROSS-CULTURAL VARIATIONS IN SF-12 SCORES AMONG INDIVIDUALS WITH VARIOUS HEALTH CONDITIONS

    Sep 1, 2001, 00:00

  • PID16- COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING

    Sep 1, 2001, 00:00

  • CV3- VASOPEPTIDASE INHIBITOR REDUCES IN-HOSPITAL COSTS FOR CONGESTIVE HEART FAILURE PATIENTS- RESULTS FROM THE IMPRESS TRIAL

    Sep 1, 2001, 00:00

  • WW9- THE USE OF MULTI-ATTRIBUTE ANALYSIS AND PAIR-WISE COMPARISONS FOR GROUP DECISION-MAKING

    Sep 1, 2001, 00:00

  • PPN14- A PROGNOSTIC MODEL TO PREDICT QUALITY OF LIFE CHANCES AFTER SUBARACHNOID HEMORRHAGE

    Sep 1, 2001, 00:00

  • PID28- COMPARING DIFFERENCES IN CLINICAL EFFECTIVENESS, NEPHROTOXICITY, AND COST-EFFECTIVENESS OF AMINOGLYCOSIDE THERAPY BETWEEN ALTERNATIVE DOSING PROTOCOLS

    Sep 1, 2001, 00:00

  • PMA13- RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION- II. A MONTE CARLO SIMULATION USING DISCRETE DATA

    Sep 1, 2001, 00:00

  • WW3- ISSUES AND PROBLEMS ENCOUNTERED IN MODELS ON PREVENTION OF DEEP VENOUS THROMBOSIS (DVT)

    Sep 1, 2001, 00:00

  • PAM12- COST-MINIMIZATION ANALYSIS OF THE TREATMENT OF RHEUMATOID ARTHRITIS WITH LEFLUNOMIDE IN COMPARISON WITH THE COMBINATION OF INFLIXIMAB AND METHOTREXATE

    Sep 1, 2001, 00:00

  • PQP6- HEALTH UTILITIES INDEX MARK 3- AGREEMENT BETWEEN RATERS AND BETWEEN MODALITIES OF ADMINISTRATION

    Sep 1, 2001, 00:00

  • PID19- AN ECONOMIC ANALYSIS OF CEFDINIR VERSUS LORACARBEF FOR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS

    Sep 1, 2001, 00:00

  • PHP4- DEVELOPING A COMPREHENSIVE PERFORMANCE MEASUREMENT DATA SET FOR PHARMACEUTICAL BENEFIT MANAGEMENT PROGRAMS

    Sep 1, 2001, 00:00

  • PID9- COST-EFFECTIVENESS OF INTERFERON ALFA THERAPY FOR CHRONIC HEPATITIS C WITH CIRRHOSIS

    Sep 1, 2001, 00:00

  • PMI11- FEASIBILITY OF A DATABASE APPROACH TO ADHERENCE WITH OSTEOPOROSIS THERAPY

    Sep 1, 2001, 00:00

  • PCN15- QOL CHANGE OVER TIME POST-REINFUSION OF PBPC IN HIGH DOSE TREATMENT OF NON-HODGKINS FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM USE

    Sep 1, 2001, 00:00

  • POD5- THE COST EFFECTIVENESS OF AN EXTRACORPOREAL LIVER ASSIST DEVICE FOR PATIENTS WITH FULMINANT HEPATIC FAILURE

    Sep 1, 2001, 00:00

  • PHP5- USING PRESCRIBING DATA TO ESTIMATE PREVALENCE OF CHRONIC ILLNESS IN THE REPUBLIC OF IRELAND

    Sep 1, 2001, 00:00

  • PMH32- BARRIERS TO THE USE OF MEDICATIONS TO TREAT ALCOHOLISM

    Sep 1, 2001, 00:00

  • PCV33- COST-ANALYSIS OF CABG SURGERY IN PATIENTS WITH AND WITHOUT RETHORACOTOMY FROM THE HOSPITAL PERSPECTIVE IN GERMANY

    Sep 1, 2001, 00:00

  • PIN1- IMPACT OF INFLUENZA AND TREATMENT WITH OSELTAMIVIR ON INDIVIDUALS DAILY ACTIVITIES AND RETURN TO NORMAL ACTIVITY

    Sep 1, 2001, 00:00

  • CV6- EXCESS MORBIDITY AND COST OF FAILING TO ACHIEVE TARGETS FOR BLOOD PRESSURE CONTROL IN THE ELDERLY

    Sep 1, 2001, 00:00

  • PHP2- GASTROINTESTINAL DRUG POLICY, DRUG SELECTION AND RESOURCE UTILIZATION-A COMPARISON OF THE CANADIAN PROVINCES OF QUEBEC AND ONTARIO

    Sep 1, 2001, 00:00

  • PCN23- DISEASE MODELING- DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL

    Sep 1, 2001, 00:00

  • PHP10- THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE

    Sep 1, 2001, 00:00

  • PDG26- THE IMPACT OF THE USE OF NEXIUM ON THE OVERALL PPI BUDGET IN GREECE

    Sep 1, 2001, 00:00

  • PCV27- COST-EFFECTIVENESS ANALYSIS OF A CHEST PAIN UNIT-A RE-STRUCTURED APPROACH IN RISK STRATIFICATION OF CHEST PAIN

    Sep 1, 2001, 00:00

  • PND14- QUALITY OF LIFE OF WOMEN SUFFERING FROM MENSTRUAL MIGRAINE AND RELATIONSHIP WITH MOOD

    Sep 1, 2001, 00:00

  • PHP17- A EUROPEAN HEALTH STATUS INDEX BASED ON PREFERENCES OF THE GENERAL PUBLIC

    Sep 1, 2001, 00:00

  • ND3- COST-EFFECTIVENESS OF CABERGOLINE COMPARED TO LEVODOPA IN EARLY PARKINSONS DISEASE IN SWEDEN

    Sep 1, 2001, 00:00

  • PCV14- IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)- AN ANALYSIS OF BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA

    Sep 1, 2001, 00:00

  • PPN1- AN INTERNET STUDY OF WTP FOR MIGRAINE PHARMACOTHERAPIES

    Sep 1, 2001, 00:00

  • PDG2- RISK OF DIABETES AMONG RISPERIDONE AND OLANZAPINE USERS

    Sep 1, 2001, 00:00

  • CN5- A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA- THE ULL-27 QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • PDB10- THE COST OF NEW ONSET DIABETES MELLITUS AMONG US RENAL TRANSPLANT RECIPIENTS

    Sep 1, 2001, 00:00

  • PCN13- PHARMACOECONOMIC ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH DOCETAXEL-CISPLATIN, PACLITAXEL-CISPLATIN AND PACLITAXEL-CARBOPLATIN

    Sep 1, 2001, 00:00

  • PMH14- DEFICIT SYNDROME AND DRUG USE PATTERNS IN COMMUNITY-BASED SCHIZOPHRENIA CARE

    Sep 1, 2001, 00:00

  • PHP20- THE ECONOMIC BURDEN OF PHYSICAL INACTIVITY IN SWITZERLAND

    Sep 1, 2001, 00:00

  • PMI4- MARKOV MODELLING TO CONVERT TRIAL-BASED COST-EFFECTIVENESS INFORMATION TO OTHER COUNTRIES-THE TIOTROPIUM EXAMPLE

    Sep 1, 2001, 00:00

  • PMH1- SHOULD THE 51 ITEMS OF THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP-51) BE WEIGHTED?

    Sep 1, 2001, 00:00

  • PCV42- PATIENTS WILLINGNESS TO PAY FOR PHARMACIST MANAGED WARFARIN THERAPY AT COMMUNITY PHARMACIES

    Sep 1, 2001, 00:00

  • PCV18- FRAMINGHAM RISK EQUATIONS PREDICT HOSPITAL USAGE AND MORTALITY

    Sep 1, 2001, 00:00

  • PMI27- FACTORS INFLUENCING COMPLETION OF THE EUROQOL EQ-5D GENERIC QOL QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • PCN11- ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PCN4- COST-EFFECTIVENESS OF URATE OXIDASE IN PREVENTION AND TREATMENT OF SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES

    Sep 1, 2001, 00:00

  • PAO4- THE COST-EFFECTIVENESS OF CELECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS IN POLAND

    Sep 1, 2001, 00:00

  • PCN7- COST OF THE POST-PBPC REINFUSION PERIOD IN HIGH DOSE TREATMENT OF NON-HODGKINS FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM

    Sep 1, 2001, 00:00

  • PDG15- THE COST OF TREATING DIABETIC FOOT ULCERS (DFU) WITH APLIGRAF IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCN17- AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF ADVANCED COLORECTAL CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PQP9- QUALITY OF LIFE OF PATIENTS WITH FABRY DISEASE

    Sep 1, 2001, 00:00

  • PCV28- CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER

    Sep 1, 2001, 00:00

  • PCV8- PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS- DATABASE ANALYSIS IN FRANCE

    Sep 1, 2001, 00:00

  • PHP6- INSURANCE CLAIMS AS A DEVICE FOR MEASURING THE PHARMACISTS SUBSTITUTION RIGHT IN A FRENCH DEPARTMENT

    Sep 1, 2001, 00:00

  • PGI13- FACTORS ASSOCIATED WITH PHYSICIAN KNOWLEDGE OF WHETHER PRESCRIPTION DRUGS ARE ON FORMULARY

    Sep 1, 2001, 00:00

  • PHP12- ACUTE CARE ELDERLY UNITS- THEIR PREVALENCE, CHARACTERISTICS AND DETERMINANTS

    Sep 1, 2001, 00:00

  • PCV17- QUALITY OF LIFE AND PATIENT PREFERENCE AS PREDICTORS FOR RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE; INTERIM ANALYSIS

    Sep 1, 2001, 00:00

  • PND13- TREATMENT AND QUALITY OF LIFE AMONG PEOPLE WITH MIGRAINES

    Sep 1, 2001, 00:00

  • PIN11- A COST BENEFIT ANALYSIS OF TWO ALTERNATIVE MASS IMMUNIZATION PROGRAMS WITH A CONJUGATE VACCINE AGAINST MENINGOCCOCAL DISEASE TYPE C

    Sep 1, 2001, 00:00

  • PAR2- USE OF RESPIRATORY ASSIST DEVICES BY MEDICARE BENEFICIARIES

    Sep 1, 2001, 00:00

  • CN2- RESOURCE CONSUMPTION RELATED TO MUCOSITIS IN LYMPHOMA PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBPC TRANSPLANTATION

    Sep 1, 2001, 00:00

  • PCV11- COST OF WARFARIN TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE

    Sep 1, 2001, 00:00

  • PAR9- VALIDATION OF A RATING INSTRUMENT ASSESSING THE INHALATION SKILLS OF CHILDREN WITH ASTHMA

    Sep 1, 2001, 00:00

  • PMH2- TREATMENT COURSE AND CHARGES FOR DEPRESSED PATIENTS TREATED WITH SERTRALINE, VENLAFAXINE, AND VENLAFAXINE XR IN THE MANAGED CARE SETTING

    Sep 1, 2001, 00:00

  • Mathematical Models for Formulary Committees

    Sep 1, 2001, 00:00

  • PCN25- A QUALITY OF LIFE AUDIT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING CHEMOTHERAPY AT ONE INSTITUTION

    Sep 1, 2001, 00:00

  • PPN7- A MODEL FOR PREDICTING THE INCIDENCE OF MIGRAINE IN THE IDAHO MEDICAID POPULATION

    Sep 1, 2001, 00:00

  • PKU2- AN ECONOMIC MODEL OF UNSTABLE BLADDER IN ITALY

    Sep 1, 2001, 00:00

  • PGI5- HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHNS DISEASE

    Sep 1, 2001, 00:00

  • PQP3- DEFINING CLINICALLY MEANINGFUL CHANGE IN HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • POD6- ECONOMIC EVALUATION OF TREATING ERECTILE DYSFUNCTION IN SPAIN- THE PRIMARY CARE APPROACH VERSUS SPECIALIZED CARE

    Sep 1, 2001, 00:00

  • PCV16- COST-EFFECTIVENESS OF AMLODIPINE TREATMENT IN PATIENTS WITH CORONARY ARTERY DISEASE IN THE U.K

    Sep 1, 2001, 00:00

  • PAR1- COST OF ASTHMA IN CHILDREN IN VLADIVOSTOK

    Sep 1, 2001, 00:00

  • PHP14- THE CURRENT STATUS AND FUTURE PROSPECTS FOR PHARMACOECONOMICS IN GREECE

    Sep 1, 2001, 00:00

  • PDG11- HEALTH AND ECONOMIC OUTCOMES OF A NEW ORAL DIABETES DRUG, PIOGLITAZONE (ACTOSNF, TAKEDA), IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN NORWAY

    Sep 1, 2001, 00:00

  • POD14- COST-EFFECTIVENESS ANALYSIS OF THE SPECTRON VERSUS CHARNLEY HIP PROSTHESES

    Sep 1, 2001, 00:00

  • PAM16- COST IMPACT OF COX-2 INHIBITORS IN A MANAGED CARE PLAN- IMPLICATIONS FOR FORMULARY DECISION-MAKING

    Sep 1, 2001, 00:00

  • HP1- ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)

    Sep 1, 2001, 00:00

  • PCV31- CLOSURE OF ATRIAL SEPTAL DEFECT- MEDICO-ECONOMIC ARGUMENTS TO CHOOSE BETWEEN INVASIVE SURGERY AND PERCUTANEOUS TECHNIQUE USING SEPTAL OCCLUDER

    Sep 1, 2001, 00:00

  • MH1- THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PND8- IMPLICATIONS OF PRESCRIBING FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)- INTRODUCING A TREATMENT ALGORITHM FOR GLATIRAMER ACETATE (COPAXONE)

    Sep 1, 2001, 00:00

  • PHP8- THE USE OF ECONOMIC INFORMATION IN HOSPITAL FORMULARY DEVELOPMENT IN A FRENCH REGION

    Sep 1, 2001, 00:00

  • PRP13- IMPACT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN FRANCE

    Sep 1, 2001, 00:00

  • PDG1- THE OUTCOMES OF LONG-TERM TREATMENT OF A NEW ORAL DIABETES DRUG PIOGLITAZONE (ACTOS ) IN THE MANAGEMENT OF TYPE 2 DIABETES IN FINLAND

    Sep 1, 2001, 00:00

  • PHP12- BARRIERS THAT PREVENT THE USE OF ECONOMIC EVALUATIONS IN HOSPITAL FORMULARY DECISION-MAKING

    Sep 1, 2001, 00:00

  • CN1- UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR)

    Sep 1, 2001, 00:00

  • PMA6- THE REDUCTION OF SAMPLE SIZE FOR A COST-EFFECTIVENESS TRIAL USING A NEW METHOD- THE EIGHT CASES IN JAPAN

    Sep 1, 2001, 00:00

  • PND9- IMPACT OF RIVASTIGMINE ON ANTIPSYCHOTIC UTILIZATION AND COST IN ALZHEIMERS DISEASE

    Sep 1, 2001, 00:00

  • PAM13- A COST-EFFECTIVENESS MODEL COMPARING CELECOXIB AND ROFECOXIB TO TRADITIONAL NSAIDS FOR OSTEOARTHRITIS TREATMENT

    Sep 1, 2001, 00:00

  • PGI10- IRRITABLE BOWEL SYNDROME COSTS SICKNESS FUNDS DM 2.8 BILLION PER YEAR

    Sep 1, 2001, 00:00

  • PDG25- ECONOMIC DIFFERENTIATION BETWEEN PPIS IN THE TREATMENT OF REFLUX ESOPHAGITIS RELATED TO GERD

    Sep 1, 2001, 00:00

  • PID1- EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS- A META-ANALYSIS REVISITED

    Sep 1, 2001, 00:00

  • MD4- INCLUSION OF INDIRECT COST IN ECONOMIC OUTCOMES ANALYSES OF MEDICAL DEVICES- HOW IMPORTANT IS IT?

    Sep 1, 2001, 00:00

  • POD7- THE EF-VAS- A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT

    Sep 1, 2001, 00:00

  • PID21- THE COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE IN THE TREATMENT OF CHRONIC HEPATITIS B IN POLAND

    Sep 1, 2001, 00:00

  • PAM6- COST-EFFECTIVENESS OF ROFECOXIB VERSUS NSAIDS IN THE TREATMENT OF OSTEOARTHRITIS

    Sep 1, 2001, 00:00

  • EM4- CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES?

    Sep 1, 2001, 00:00

  • PRP11- EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA

    Sep 1, 2001, 00:00

  • PCV28- COST-CONSEQUENCES OF LOW-MOLECULARWEIGHT HEPARIN (LMWH) COMPARED WITH HEPARIN IN UNSTABLE CORONARY ARTERY DISEASE IN JAPAN

    Sep 1, 2001, 00:00

  • PID2- IMPACT OF CYTOMEGALOVIRUS (CMV)-RELATED READMISSION ON POST HEART TRANSPLANT RESOURCE USE

    Sep 1, 2001, 00:00

  • PCV8- COST-EFFECTIVENESS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION- DECISION ANALYSIS TAKING INTO ACCOUNT SIDE-EFFECTS

    Sep 1, 2001, 00:00

  • PUR2- EVIDENCE OF DISEASE PROGRESSION IN ADULT PATIENTS WITH AN OVERACTIVE BLADDER (OAB)

    Sep 1, 2001, 00:00

  • PHP9- THE INFLUENCE OF UPDATING THE ISRAELI NATIONAL DRUG LIST ON AVERAGE NUMBER OF DRUGS PRESCRIBED TO A PATIENT

    Sep 1, 2001, 00:00

  • PUR1- HEALTH STATUS OF ELDERLY DIALYSIS PATIENTS

    Sep 1, 2001, 00:00

  • PAM21- MANUAL THERAPY IS MORE COST-EFFECTIVE THAN PHYSICAL THERAPY AND GP CARE FOR PATIENTS WITH NECK PAIN

    Sep 1, 2001, 00:00

  • Impact of Long-Term Complications on Quality of Life in Patients with Type 2 Diabetes not Using Insulin

    Sep 1, 2001, 00:00

  • PMH15- A RETROSPECTIVE ECONOMIC EVALUATION OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PID24- COST COMPARISON OF GATIFLOXACIN VERSUS LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN AN OUTPATIENT POPULATION

    Sep 1, 2001, 00:00

  • PMA10- DESCRIPTION OF COST/EFFECTIVENESS RATIO DISTRIBUTIONS

    Sep 1, 2001, 00:00

  • PND7- ESTIMATION OF THE COSTS OF MULTIPLE SCLEROSIS BASED ON 157 FRENCH PATIENTS

    Sep 1, 2001, 00:00

  • PCV20- COST-EFFECTIVENESS STUDY TO DETERMINE THE IMPACT OF A TOBACCO OUTREACH PROGRAM FOR ADOLESCENTS

    Sep 1, 2001, 00:00

  • PMH11- SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)- THE IMPACT OF CLINICAL SYNDROME, ANTIPSYCHOTIC MEDICATION TREATMENT AND ADHERENCE ON OUTPATIENT PSYCHIATRIC UTILIZATION

    Sep 1, 2001, 00:00

  • PAR17- PATIENT SATISFACTION WITH NON-SEDATING ANTIHISTAMINES

    Sep 1, 2001, 00:00

  • PUR4- ANALYSIS OF COMORBIDITY IN OVERACTIVE BLADDER AND URINARY INCONTINENCE IN A MANAGED CARE ORGANIZATION

    Sep 1, 2001, 00:00

  • IN2- THE ECONOMIC BURDEN OF VIRAL RESPIRATORY INFECTION IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PCN20- COST MINIMIZATION ANALYSIS OF CEFEPIME VERSUS IMIPENEM-CILASTATINE IN CANCER PATIENTS WITH SHORT-DURATION FEBRILE NEUTROPENIA

    Sep 1, 2001, 00:00

  • PCV4- ASSESSING THE IMPACT OF HYPERLIPIDEMIA TREATMENT WITH PRAVASTATIN AND SIMVASTATIN IN A LARGE COUNTY INSTITUTION

    Sep 1, 2001, 00:00

  • PMH13- THE DIRECT COST OF RISPERIDONE VERSUS HALOPERIDOL THERAPY FOR CHRONIC SCHIZOPHRENIA IN POLAND

    Sep 1, 2001, 00:00

  • PMH3- PATIENT MEDICATION ATTITUDE AFTER SWITCHING TOZIPRASIDONE FROM OTHER ANTIPSYCHOTICS

    Sep 1, 2001, 00:00

  • PAR18- COSTS OF TREATING COPD IN ITALY- A BURDEN OF ILLNESS STUDY

    Sep 1, 2001, 00:00

  • CN1- BRIEF ASSESSMENT OF PRIORITY SYMPTOMS IN HORMONE REFRACTORY PROSTATE CANCER (HRPCA)

    Sep 1, 2001, 00:00

  • PPN11- THE MIGRAINE IN FRANCE IN 2000- EPIDEMIOLOGICAL DATA

    Sep 1, 2001, 00:00

  • QL3- QUALITY OF LIFE IN PRODUCT LABELING- A REVIEW OF MARKETED DRUG PRODUCTS

    Sep 1, 2001, 00:00

  • PCV29- PERSISTENCY OF TREATMENT IN PATIENTS INITIATED ON FIVE DIFFERENT CLASSES OF ANTIHYPERTENSIVE THERAPY- A PHARMACO-UTILIZATION AND PHARMACO-ECONOMIC ANALYSIS

    Sep 1, 2001, 00:00

  • PMH10- HEALTH OUTCOMES OF CHILDHOOD ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- HEALTH CARE USE AND WORK STATUS OF CAREGIVERS

    Sep 1, 2001, 00:00

  • PMH9- HEALTH CARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION

    Sep 1, 2001, 00:00

  • PCN28- DETECTING RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER IN CLINICALPRACTICE- NEED FOR A CHANGE?

    Sep 1, 2001, 00:00

  • MH2- EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE

    Sep 1, 2001, 00:00

  • PMH4- DRUG SELECTION, DOSING, AND UTILIZATION PATTERNS AMONG DEPRESSED PATIENTS TREATED WITH SSRIS AND VENLAFAXINE IN US MANAGED CARE PLANS

    Sep 1, 2001, 00:00

  • PMI26- ASSESSMENT OF RESPONDENT ACCEPTABILITY OF UTILITY MEASURES- DISCRIMINATORY POWER OF GRAPHIC POSITIONING SCALE VERSUS TRADITIONAL SCALING MEASURES

    Sep 1, 2001, 00:00

  • Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C- Clinical and Economic Implications

    Sep 1, 2001, 00:00

  • PGI17- COMPARISON OF GENERIC VERSUS DISEASE SPECIFIC TOOLS FOR THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CROHNS DISEASE

    Sep 1, 2001, 00:00

  • PIN13- CAN VARICELLA BE ELIMINATED BY UNIVERSAL CHILDHOOD VACCINATION COST-BENEFICIALLY? EXAMPLES FOR EUROPE

    Sep 1, 2001, 00:00

  • MS3- CORRELATION OF A GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE AND SELF-ADMINISTERED RHEUMATOID ARTHRITIS DISEASE ACTIVITY INSTRUMENT

    Sep 1, 2001, 00:00

  • MD1- COST-EFFECTIVENESS OF AIRLINE DEFIBRILLATORS- IS PEACE OF MIND MORE IMPORTANT THAN SAVING LIVES?

    Sep 1, 2001, 00:00

  • PRP12- ASTHMA KNOWLEDGE AND QUALITY OF LIFE (QOL) OF ADULT ASTHMATICS

    Sep 1, 2001, 00:00

  • PIN12- BURDEN OF ILLNESS IMPOSED BY SEVERE SEPSIS IN GERMANY

    Sep 1, 2001, 00:00

  • PND2- COMPARISON OF ADVERSE REACTION REPORTS FOR RIVASTIGMINE AND DONEPEZIL USING THE FDAS ADVERSE EVENT REPORTING SYSTEM

    Sep 1, 2001, 00:00

  • PMA16- CONFIRMATION OF THE DECISION RULES AND ASSUMPTIONS FOR A MODEL OF DIABETES TREATMENT USING AN EXPERT PANEL

    Sep 1, 2001, 00:00

  • PDG14- AN ASSESSMENT OF THE COSTEFFECTIVENESS OF PIOGLITAZONE (ACTOSNF, TAKEDA) IN TYPE 2 DIABETES MELLITUS IN DENMARK

    Sep 1, 2001, 00:00

  • QL2- ESTIMATING PATIENTS PREFERENCES IN TREATMENT CHOICES INVOLVING RISK- A NEW MODIFIED STANDARD GAMBLE METHOD

    Sep 1, 2001, 00:00

  • PCV3- ENOXAPARIN - A PHARMACOECONOMIC REVIEW OF ITS USE IN THROMBOEMBOLIC PROPHYLAXIS

    Sep 1, 2001, 00:00

  • PIN7- PHARMACOECONOMIC EVALUATION OF IMIQUIMOD (ALDARA) FOR THE TREATMENT OF EXTERNAL GENITAL WARTS IN A DUTCH TREATMENT ENVIRONMENT

    Sep 1, 2001, 00:00

  • WW13- CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH

    Sep 1, 2001, 00:00

  • PGI11- CHARACTERIZATION AND MARKOV MODELING OF GASTROESOPHAGEAL REFLUX DISEASE STATES IN A LARGE HEALTH CARE PLAN

    Sep 1, 2001, 00:00

  • PMH5- FROM FIRST TO SECOND- IMPACT OF PARTICIPANT CHARACTERISTICS ON THE TIME TO FIRST SWITCH IN A SCHIZOPHRENIA POPULATION

    Sep 1, 2001, 00:00

  • PIN21- ANTIBIOTIC PROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY- ASSESSMENT OF GLOBAL CONFORMITY TO FRENCH GUIDELINES

    Sep 1, 2001, 00:00

  • PIN5- COST-UTILITY ANALYSIS OF A PNEUMOCOCCAL/MENINGOCOCCAL COMBINATION VACCINE FOR INFANTS

    Sep 1, 2001, 00:00

  • DS3- DESIGN AND ANALYSIS OF UNIT COST ESTIMATION STUDIES- HOW MANY TYPES OF HOSPITALIZATION? HOW MANY COUNTRIES?

    Sep 1, 2001, 00:00

  • PMH17- TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA- ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES USING A MARKOV MODEL

    Sep 1, 2001, 00:00

  • DS2- POWER CALCULATIONS FOR WIDELY USED PATIENT-REPORTED OUTCOMES (PRO) MEASURES IN WOMENS HEALTH TRIALS

    Sep 1, 2001, 00:00

  • PHP16- THE VALUE OF VARIOUS FORMS OF EVIDENCE IN DRUG FORMULARY DECISION MAKING

    Sep 1, 2001, 00:00

  • PMI6- ESTIMATING AND COMPARING RESOURCE USE AND COST OF G-CSF USE IN CHEMOTHERAPY WITH THE ACTIVITY-BASED COSTING (ABC) METHOD IN THREE SETTINGS

    Sep 1, 2001, 00:00

  • PCN16- CHEMOTHERAPY TREATMENT IN NEWLY DIAGNOSED BREAST CANCER PATIENTS IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PID4- ECONOMIC COST OF HIV INFECTION IN UNTREATED WORKERS- AN EMPLOYERS PERSPECTIVE

    Sep 1, 2001, 00:00

  • PAR6- PROPHYLACTIC MEDICATION UTILIZATION AND HEALTH CARE COSTS IN OLDER ADULTS WITH CHRONIC PULMONARY AILMENTS

    Sep 1, 2001, 00:00

  • PCV15- ECONOMIC EVALUATION OF OUTPATIENT ANTICOAGULANT/ANTIPLATELET THERAPY FOLLOWING CORONARY STENTING IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMI21- ESTIMATING INFLUENZA-RELATED EXCESS HOSPITAL ADMISSIONS

    Sep 1, 2001, 00:00

  • PGI1- EFFECTS ON HEALTH CARE CONTACTS AND DAYS ABSENT FROM WORK WITH BUDESONIDE CIR CAPSULES IN THE MAINTENANCE TREATMENT OF CROHNS DISEASE IN A US SETTING

    Sep 1, 2001, 00:00

  • PCN12- THE RELATIONSHIP OF AGE AND DURATION OF HORMONAL THERAPY USE AMONG PATIENTS DIAGNOSED WITH CANCER OF THE PROSTATE

    Sep 1, 2001, 00:00

  • PCN22- COST-EFFECTIVENESS ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER

    Sep 1, 2001, 00:00

  • PHP15- IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS

    Sep 1, 2001, 00:00

  • PHP5- POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS IN COMPARISON TO INTERNATIONAL HEALTH ECONOMIC GUIDELINES

    Sep 1, 2001, 00:00

  • PHP1- THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS- EXPERIENCES FROM SWEDEN

    Sep 1, 2001, 00:00

  • PMI8- DO HEALTH CARE PURCHASERS PREFER PAYING FOR LIFE EXTENSION OR QUALITY OF LIFE IMPROVEMENT?

    Sep 1, 2001, 00:00

  • PIN17- HOW CAN PRODUCTS WITH MARGINAL EFFICACY SAVE MONEY? THE EXAMPLE OF A NON SPECIFIC, IMMUNOSTIMULATING, PREVENTIVE TREATMENT FOR RECURRENT UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN

    Sep 1, 2001, 00:00

  • RP2- THE NET COST OF ASTHMA TO A US PUBLIC MEDICAID PROGRAM

    Sep 1, 2001, 00:00

  • PDB2- USING RETROSPECTIVE CLAIMS DATA TO DESIGN CLINICAL SAFETY SURVEILLANCE OF THIAZOLIDINEDIONE DRUGS

    Sep 1, 2001, 00:00

  • PMA9- BAYESIAN OR CLASSICAL DESIGN AND ANALYSIS- DOES IT MAKE A DIFFERENCE??

    Sep 1, 2001, 00:00

  • PCV10- A PHARMACOECONOMIC ANALYSIS OF PATIENT OUTCOMES IN THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES) IN NORWAY AND CANADA

    Sep 1, 2001, 00:00

  • PCV39- COST OF TREATMENT OF HYPERCHOLESTEROLAEMIA TO NHF GOALS IN AUSTRALIA

    Sep 1, 2001, 00:00

  • PCV37- THE COST-EFFECTIVENESS OF STATINS- EVIDENCE FROM THE ACCESS TRIAL

    Sep 1, 2001, 00:00

  • PDG9- THE EVENT AND STATE COST OF COMPLICATIONS OF DIABETES IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCV31- A DECISION-ANALYSIS MODEL FOR ENHANCING MEDICATION ADHERENCE IN PATIENTS TAKING STATINS

    Sep 1, 2001, 00:00

  • HP2- THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS

    Sep 1, 2001, 00:00

  • PRP6- ASMACARE STUDY. ASSESSMENT OF THE IMPACT OF AN INTERVENTION DESIGNED TO IMPROVE THE MANAGEMENT OF ASTHMA PATIENTS

    Sep 1, 2001, 00:00

  • PHP2- ATTITUDE OF PHYSICIANS TOWARD FORMULARIES AND SERVICES PROVIDED BY PHARMACIST

    Sep 1, 2001, 00:00

  • PCV2- COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION

    Sep 1, 2001, 00:00

  • PGI3- A PROSPECTIVE, RANDOMIZED COST ANALYSIS OF MEPERIDINE AND MIDAZOLAM VERSUS PROPOFOL FOR COMPLEX UPPER ENDOSCOPY PROCEDURES

    Sep 1, 2001, 00:00

  • PWM6- COST-EFFECTIVENESS OF INTRAVAGINAL PROSTAGLANDIN E2 GEL AND INTRAVAGINAL MISOPROSTOL FOR PREINDUCTION CERVICAL RIPENING

    Sep 1, 2001, 00:00

  • PND10- CONCOMITANT DRUG USE IMPLICATIONS IN ALZEIMERS DISEASE PATIENTS USING DONEPEZIL

    Sep 1, 2001, 00:00

  • PAO10- PSYCHOMETRIC VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)

    Sep 1, 2001, 00:00

  • PKU5- HEALTH-RELATED CONSEQUENCES AND COSTS OF OVERACTIVE BLADDER

    Sep 1, 2001, 00:00

  • PMI10- THE NICE' APPROACH TO PHARMACOECONOMICS- AN ECONOMICS PERSPECTIVE

    Sep 1, 2001, 00:00

  • DG4- DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTH CARE PLAN

    Sep 1, 2001, 00:00

  • PEE9- THE SOCIETAL COST OF ATOPIC DERMATITIS IN GERMANY

    Sep 1, 2001, 00:00

  • PDG8- A POPULATION STUDY OF HEALTH-CARE COSTS ASSOCIATED WITH HYPOGLYCAEMIA

    Sep 1, 2001, 00:00

  • PMI22- MICE (MODULE FOR STANDARDISED INDIRECT COST ESTIMATION) INCREASES THE TRANSFERABILITE OF STUDY RESULTS

    Sep 1, 2001, 00:00

  • PHP22- PERCEIVED QUALITY OF LIFE AND MEDICINE CONSUMPTION IN ELDERLY OUTPATIENTS

    Sep 1, 2001, 00:00

  • MH3- RECENT WEIGHT GAIN AND THE COST OF ACUTE SERVICE USE AMONG INDIVIDUALS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PEE2- THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYERS PERSPECTIVE

    Sep 1, 2001, 00:00

  • PPN5- COMPARISON OF COSTS AND COST-EFFECTIVENESS OF OXCARBAZEPINE AND SODIUM VALPROATE FOR NEW/RECENT ONSET PARTIAL SEIZURES

    Sep 1, 2001, 00:00

  • PEE11- PSORIASIS AND EVERYDAY LIFE- FIRST RESULTS

    Sep 1, 2001, 00:00

  • PPN12- DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE

    Sep 1, 2001, 00:00

  • PPN18- COST SAVINGS IN MIGRAINE ASSOCIATED WITH LESS CHEST PAIN ON NEW TRIPTAN THERAPY

    Sep 1, 2001, 00:00

  • PRP4- COST-CONSEQUENCE ANALYSIS OF TIOTROPIUM VERSUS IPRATROPIUM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Sep 1, 2001, 00:00

  • PID20- TARGETING POPULATIONS AT-RISK FOR URINARY TRACT INFECTION COMPLICATION

    Sep 1, 2001, 00:00

  • PRP14- ASSESSING PATIENTS PREFERENCES FOR CONVENTIONAL AND HOMEOPATHIC TREATMENT FOR ASTHMA-A CONJOINT ANALYSIS STUDY

    Sep 1, 2001, 00:00

  • PCV19- DISCRIMINABILITY FOR RISK OF CARDIOVASCULAR EVENTS

    Sep 1, 2001, 00:00

  • PUR7- CLINICAL CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE SCORES AND SUBSCALES AMONG CONSULTING AND NON-CONSULTING INDIVIDUALS WITH STRESS URINARY INCONTINENCE

    Sep 1, 2001, 00:00

  • PAM1- JOINT COUNTS IN PATIENTS WITH NEW ONSET RHEUMATOID ARTHRITIS- PATIENT VS. PHYSICIAN ASSESSMENT

    Sep 1, 2001, 00:00

  • RS4- A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA

    Sep 1, 2001, 00:00

  • PMH19- IDENTIFICATION AND ONE-YEAR COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CLAIMS DATA ANALYSIS

    Sep 1, 2001, 00:00

  • QL2- LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH- AN ANALYSIS OF US SURVEY DATA

    Sep 1, 2001, 00:00

  • PMI20- A REAL OPTION APPROACH TO VALUING PHARMACEUTICAL INVESTMENTS AND FIRMS

    Sep 1, 2001, 00:00

  • PRP3- SPECIFIC IMMUNOTROPIC THERAPY - ASPECTS OF COST-EFFECTIVENESS

    Sep 1, 2001, 00:00

  • PEE6- COST-EFFECTIVENESS OF ARTIFICIAL SKIN SUBSTITUTE VS ALLOGRAFT FOR BURN PATIENTS

    Sep 1, 2001, 00:00

  • PAM20- COST-EFFECTIVENESS OF ACETYLCISTEINE AND DIMETHYLSULPHOXIDE (DMSO) 50 FOR THE TREATMENT OF PATIENTS WITH REFLEX SYMPATHIC DYSTROPHY

    Sep 1, 2001, 00:00

  • WW17- SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES- FIRST PRINCIPLES

    Sep 1, 2001, 00:00

  • PHP15- A SURVEY OF PUBLIC HOSPITAL PHARMACISTS IN SINGAPORE ON THEIR VIEWS ABOUT THE FORMULARY' AND ITS DECISION-MAKING PROCESS

    Sep 1, 2001, 00:00

  • PEE2- COSTS AND CONSEQUENCES OF OLOPATADINE 0.1 IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS

    Sep 1, 2001, 00:00

  • PAO8- THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS

    Sep 1, 2001, 00:00

  • PUR8- THE INFLUENCE OF RACE ON SF-36 SCORES OF DIALYSIS PATIENTS

    Sep 1, 2001, 00:00

  • PDB5- A COST-MINIMIZATION STUDY TO DETERMINE THE IMPACT OF ADDING GLUCOVANCE TO A COUNTY HOSPITAL FORMULARY

    Sep 1, 2001, 00:00

  • PMH18 HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION

    Sep 1, 2001, 00:00

  • PIN20- ESTIMATING THE RETURN ON INVESTMENT FOR TUBERCULOSIS DRUGS

    Sep 1, 2001, 00:00

  • PCV7- ENOXAPARIN - A PHARMACOECONOMIC REVIEW OF ITS USE IN ACUTE CORONARY SYNDROMES

    Sep 1, 2001, 00:00

  • PDB15- DOES PATIENT EXPERIENCE MATTER? TYPE II DIABETES PATIENTS STATED PREFERENCES FOR INSULIN THERAPIES

    Sep 1, 2001, 00:00

  • QL1- CAN HEALTH STATE VALUES BE PREDICTED FROM HEALTH-RELATED QUALITY OF LIFE MEASURES?

    Sep 1, 2001, 00:00

  • IN3- THE OBSERVED COSTS AND HEALTH-CARE USE OF CHILDREN IN A RANDOMIZED CONTROLLED TRIAL OF PNEUMOCOCCAL CONJUGATE VACCINE

    Sep 1, 2001, 00:00

  • PID22- AN APPRAISAL OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN PATIENTS DIAGNOSED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

    Sep 1, 2001, 00:00

  • PDG23- PHARMACEUTICAL AND HOSPITAL EXPENDITURE FOR ANTI-DYSPEPTIC TREATMENT- THE EFFECTS OF THE INTRODUCTION OF A DISEASE MANAGEMENT GUIDELINE

    Sep 1, 2001, 00:00

  • PRP2 ASTHMA MANAGEMENT AND OUTCOMES IN ITALY

    Sep 1, 2001, 00:00

  • PCV35- STOP SMOKING CESSATION TARGET- OBSERVATION PROGRAM AN EX-SMOKER IS A SMOKER IN PROGRESSION

    Sep 1, 2001, 00:00

  • PCN18- COLORECTAL CANCER SCREENING- AWARENESS, UTILIZATION, AND BARRIERS

    Sep 1, 2001, 00:00

  • PCV32- STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS

    Sep 1, 2001, 00:00

  • PCN19- COLORECTAL CANCER SCREENING TESTS- VARIATION IN PREFERENCES BASED ON GENDER AND RACE

    Sep 1, 2001, 00:00

  • PCN5- FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER - COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN

    Sep 1, 2001, 00:00

  • PMH6- PATTERNS OF COMORBIDITIES AND COPRESCRIBING AMONG DEPRESSED PATIENTS TREATED WITH SSRIS AND VENLAFAXINE IN US MANAGED CARE PLANS

    Sep 1, 2001, 00:00

  • PIN2- COST-EFFECTIVENESS OF HIV-SCREENING OF PATIENTS ATTENDING A CLINIC FOR SEXUALLY TRANSMITTED DISEASES IN AMSTERDAM

    Sep 1, 2001, 00:00

  • PMA5- A RISK ADJUSTMENT METHODOLOGY FOR CLAIMS DATA

    Sep 1, 2001, 00:00

  • PWM5- HEALTH CARE USE ATTRIBUTABLE TO PROSTATE NON-SELECTIVE ALPHA-1 ANTAGONIST INITIATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH)

    Sep 1, 2001, 00:00

  • ID3- COST-EFFECTIVENESS ANALYSIS OF AN INTRANASAL INFLUENZA VACCINE FOR HEALTHY CHILDREN

    Sep 1, 2001, 00:00

  • PDG12- CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCV24- COSTS OF HYPERTENSION IN POLAND

    Sep 1, 2001, 00:00

  • WW14- MAKING MODELS BETTER

    Sep 1, 2001, 00:00

  • ID1- DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT

    Sep 1, 2001, 00:00

  • PCV7- COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION

    Sep 1, 2001, 00:00

  • PID17 ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN

    Sep 1, 2001, 00:00

  • CE3- THE COST OF UPPER GASTRODUODENAL ENDOSCOPY- AN ACTIVITY-BASED APPROACH

    Sep 1, 2001, 00:00

  • PID26- PHARMACOECONOMIC EVALUATION OF CEFUROXIME IN ABDOMINAL HYSTERECTOMY

    Sep 1, 2001, 00:00

  • PID15- MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY- CHANGES IN THE RATE AND COST OF HOSPITALIZATIONS

    Sep 1, 2001, 00:00

  • PMH10- MANAGEMENT AND COST OF A MANIC EPISODE IN BIPOLAR DISORDER-A FRENCH STUDY

    Sep 1, 2001, 00:00

  • DG1- THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • HP2- TRANSLATING EVIDENCE TO PRACTICE IN BREAST CANCER

    Sep 1, 2001, 00:00

  • The Impact of Risk on Preference Values- Implications for Evaluations of Postmenopausal Osteoporosis Therapy

    Sep 1, 2001, 00:00

  • PID23- PATTERNS OF ANTIBIOTIC USE AND COSTS ASSOCIATED WITH EPISODES OF TREATMENT FOR COMMON OUTPATIENT RESPIRATORY-TRACT INFECTIONS- AN ANALYSIS OF MANAGED-CARE DATA

    Sep 1, 2001, 00:00

  • PPN13- DELAYS IN NURSING HOME PLACEMENT FOR PATIENTS WITH ALZHEIMERS DISEASE ASSOCIATED WITH TREATMENT WITH DONEPEZIL MAY HAVE HEALTH CARE COST-SAVING IMPLICATIONS

    Sep 1, 2001, 00:00

  • PAR4- COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Sep 1, 2001, 00:00

  • WW10- MULTINATIONAL ECONOMIC STUDIES- LESSONS LEARNED FROM TRIAL-BASED AND MODELLING STUDIES

    Sep 1, 2001, 00:00

  • PRP5- ESTIMATES OF LOST PRODUCTIVE WORK TIME ASSOCIATED WITH ALLERGIC RHINITIS (AR)

    Sep 1, 2001, 00:00

  • PND5- THE COST OF SECONDARY STROKE IN POLAND

    Sep 1, 2001, 00:00

  • PND11- DISEASE MANAGEMENT IN MIGRAINE AND TENSION-TYPE HEADACHE - RESULTS OF A SOCIO-ECONOMIC PILOT STUDY

    Sep 1, 2001, 00:00

  • PGI14- HOW IMPORTANT IS APPROPRIATE EMPIRICAL ANTIBIOTIC TREATMENT FOR INTRA-ABDOMINAL INFECTIONS?

    Sep 1, 2001, 00:00

  • PKU6- INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE) IN SIX EUROPEAN COUNTRIES

    Sep 1, 2001, 00:00

  • PCN9- ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK

    Sep 1, 2001, 00:00

  • PMH7- CHANGE IN MALADAPTIVE BEHAVIORS ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS

    Sep 1, 2001, 00:00

  • CV3- DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS?

    Sep 1, 2001, 00:00

  • PAR7- VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE

    Sep 1, 2001, 00:00

  • PHP13- INDICES FOR EVALUATION OF DRUG COST/UTILIZATION- EVERY SILVER LINING HAS A GRAY CLOUD

    Sep 1, 2001, 00:00

  • PCV3- AN ANALYSIS OF THE COST OF ADVERSE EVENTS ASSOCIATED WITH THE USE OF HMG-COA REDUCTASE INHIBITORS

    Sep 1, 2001, 00:00

  • CN4- THE IMPACT OF THE DIAGNOSIS OF CANCER ON OUT-OF-POCKET HEALTH-CARE EXPENDITURES MADE BY THE US ELDERLY

    Sep 1, 2001, 00:00

  • POD1- ESTIMATING THE SEMI-FIXED COSTS OF A DAY-CASE EPISODE

    Sep 1, 2001, 00:00

  • PHP3- MACRO-ECONOMIC ANALYSIS OF HEROIN MARKETS IN THE EU AND THE IMPACT OF SUBSTITUTION TREATMENT

    Sep 1, 2001, 00:00

  • PCN26- SYSTEMATIC ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER

    Sep 1, 2001, 00:00

  • PCV12- A COMPARISON OF HEALTH-CARE UTILIZATION AND COSTS OF PATIENTS WITH BRADYCARDIA ONLY AND BRADYCARDIA WITH ATRIAL TACHYARRHYTHMIAS IN THE US, UK AND GERMANY

    Sep 1, 2001, 00:00

  • PCV6- AVAPROMISE- A RANDOMIZED CLINICAL TRIAL FOR INCREASING COMPLIANCE THROUGH BEHAVIORAL MODIFICATION IN ESSENTIAL HYPERTENSION

    Sep 1, 2001, 00:00

  • PCN9- COST-EFFECTIVENESS OF IMAGE-GUIDED VERSUS BLIND INSERTION OF HICKMAN LINES IN ADULT CANCER PATIENTS BY NURSES

    Sep 1, 2001, 00:00

  • PGI9- COST-EFFECTIVENESS OF TREAT' HELICOBACTER PYLORI INFECTED DYSPEPTIC PATIENTS IN A PRIMARY CARE SETTING

    Sep 1, 2001, 00:00

  • PCN13- COST OF THROMBOCYTOPENIA-RELATED BLEEDING AMONG PATIENTS WITH CANCER

    Sep 1, 2001, 00:00

  • PAR22- IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES

    Sep 1, 2001, 00:00

  • POD9- AN ANALYSIS OF THE USEFULNESS AND TRANSPARENCY OF COST-EFFECTIVENESS LITERATURE FOR SURGICAL DEVICES AND PROCEDURES

    Sep 1, 2001, 00:00

  • PHP6- ACTIVITIES, FUNCTIONS AND STRUCTURE OF PHARMACY AND THERAPEUTICS COMMITTEES IN ISRAELI HOSPITALS

    Sep 1, 2001, 00:00

  • PAO2- ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS

    Sep 1, 2001, 00:00

  • PDG16- BUDGETARY IMPACT OF TREATMENT GUIDELINES-THE EXAMPLE OF TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PUR6- THE RELIABILITY AND VALIDITY OF A NEW OAB-SPECIFIC HRQL QUESTIONNAIRE (OAB-Q)

    Sep 1, 2001, 00:00

  • PHP18- A MODEL FOR COMPARING COSTS ASSOCIATED WITH PRESCRIPTION WASTAGE WITH APPLICATION TO VA PRESCRIPTION DATA

    Sep 1, 2001, 00:00

  • PMH31- PHARMACOECONOMIC EVALUATION OF THE TREATMENT WITH OLANZAPINE IN 'REVOLVING DOOR' SCHIZOPHRENIC PATIENTS

    Sep 1, 2001, 00:00

  • PMI2- SMOOTHED BOOTSTRAP FOR CONFIDENCE INTERVAL FOR COST-EFFECTIVENESS RATIOS

    Sep 1, 2001, 00:00

  • PCV5- IMPACT OF NON-COMPLIANCE ON THE COSTEFFECTIVENESS OF STATIN THERAPY

    Sep 1, 2001, 00:00

  • PND3- COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSONS DISEASE

    Sep 1, 2001, 00:00

  • WW15- IDENTIFYING THE IMPACT OF A TREATMENT ON OUTCOMES AND COSTS USING OBSERVATIONAL DATA- OVERCOMING SELECTION BIAS

    Sep 1, 2001, 00:00

  • PKU1- COST-EFFECTIVENESS ANALYSIS OF THREE SURGICAL TREATMENTS FOR FEMALE STRESS URINARY INCONTINENCE

    Sep 1, 2001, 00:00

  • The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales

    Sep 1, 2001, 00:00

  • PDG13- ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY-AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES

    Sep 1, 2001, 00:00

  • PCN21- HEALTH-RELATED QUALITY OF LIFE AFTER ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER

    Sep 1, 2001, 00:00

  • PHP7- PILOT STUDY TO DETERMINE THE DEMOGRAPHICS, REASONS, AND TYPES OF MEDICATIONS PURCHASED IN MEXICO BY US RESIDENTS

    Sep 1, 2001, 00:00

  • PAM9- COST COMPARISON OF TREATING RHEUMATOID ARTHRITIS PATIENTS WITH COX-2 INHIBITORS OR NSAIDS IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • CV4- COMPARISON BETWEEN INVESTIGATOR AND PATIENTS GLOBAL HEALTH ASSESSMENTS USING CALCULATED HUI-III AND SF-36 UTILITY VALUES

    Sep 1, 2001, 00:00

  • PMH27- COST-UTILITY ANALYSIS OF QUETIAPINE COMPARED TO RISPERIDONE IN THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS

    Sep 1, 2001, 00:00

  • WW11- USING MARKOV DECISION MODELS TO DEVELOP OPTIMAL TREATMENT PATHWAYS- AN ILLUSTRATION

    Sep 1, 2001, 00:00

  • PAR16- COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMI15- COST ANALYSIS FOR END-OF-LIFE CARE

    Sep 1, 2001, 00:00

  • PWM8- QUALITY OF LIFE IN POST-MENOPAUSAL WOMEN IN FIVE EUROPEAN COUNTRIES

    Sep 1, 2001, 00:00

  • PGI6- COST-EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI ERADICATION TRIPLE THERAPY VERSUS CONVENTIONAL THERAPY FOR GASTRIC AND DUODENAL ULCERS IN JAPAN

    Sep 1, 2001, 00:00

  • PCN17- PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS

    Sep 1, 2001, 00:00

  • DG3- A RETROSPECTIVE EVALUATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS AMONG ADULTS IN A MANAGED CARE HEALTH PLAN

    Sep 1, 2001, 00:00

  • PCN24- INCIDENCE AND COST OF HOSPITALIZATION FOR 5-FU TOXICITY AMONG MEDICARE BENEFICIARIES WITH METASTATIC COLORECTAL CANCER

    Sep 1, 2001, 00:00

  • PMH25- MENTAL WELL-BEING AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PDG3- AN ECONOMIC EVALUATION OF COMBINATION THERAPY WITH PIOGLITAZONE (ACTOS, TAKEDA) IN TYPE 2 DIABETES MELLITUS FROM A SPANISH HEALTH-CARE PERSPECTIVE

    Sep 1, 2001, 00:00

  • PMI16- VALUATION OF INFORMAL CARE

    Sep 1, 2001, 00:00

  • QL4- QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990-99

    Sep 1, 2001, 00:00

  • PMA8- DEVELOPMENT OF A CHRONIC DISEASE INDICATOR USING A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMH2- IMPROVEMENT IN QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC PATIENTS IS ASSOCIATED WITH ROBUST ACUTE TREATMENT RESPONSE OF OLANZAPINE VERSUS HALOPERIDOL

    Sep 1, 2001, 00:00

  • PAM17- IMPORTANT ISSUES IN NUMBER NEEDED TO TREAT ANALYSIS IN OSTEOPOROSIS TREATMENT

    Sep 1, 2001, 00:00

  • PDG6- COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS, TAKEDA) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN

    Sep 1, 2001, 00:00

  • PWM7- THE EFFECT AND ECONOMIC IMPACT OF STANDARDIZED ORDERS ON THE PREVENTION AND TREATMENT OF PONV IN HOSPITALIZED GYNECOLOGICAL SURGERY PATIENTS

    Sep 1, 2001, 00:00

  • PAR11- THE LONG-TERM SOCIETAL ECONOMIC AND HUMANISTIC BENEFITS OF TREATING ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) WITH GEMIFLOXACIN VERSUS CLARITHROMYCIN

    Sep 1, 2001, 00:00

  • PDG22- EVALUATION OF A GENERIC QOL INSTRUMENT (KINDL) FOR SELF-ASSESSMENT OF QOL IN SINGAPOREAN CHILDREN WITH DIABETES- A PILOT STUDY

    Sep 1, 2001, 00:00

  • PMH24- THE COST OF ACUTE HOSPITALIZATION FOR ANOREXIA NERVOSA AND BULIMIA

    Sep 1, 2001, 00:00

  • PHP14- COST ANALYSIS OF PHARMACEUTICAL SERVICES IN A TEACHING INSTITUTION

    Sep 1, 2001, 00:00

  • PMH23- THE USE OF NEFAZODONE IN THE TREATMENT OF POST TRAUMATIC STRESS DISORDER

    Sep 1, 2001, 00:00

  • PPN15- MULTIPLE PAIN RELIEF ASSESSMENT IN WOMEN UNDERGOING NATURAL VERSUS EPIDURAL DELIVERY WITH ROPIVACAIN OR BUPIVACAIN

    Sep 1, 2001, 00:00

  • PDG20- A SIMULATION MODEL TO CALCULATE LONGTERM COSTS AND LIFE EXPECTANCY DEPENDENT ON POST PRANDIAL BLOOD GLUCOSE LEVELS IN DIABETES PATIENTS

    Sep 1, 2001, 00:00

  • PDG5- MODELING THE IMPACT OF A NEW ORAL ANTI-DIABETIC TREATMENT ON DIABETES COMPLICATION COSTS IN FRANCE

    Sep 1, 2001, 00:00

  • CN4- ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PRP10- VARIATIONS IN COVERAGE FOR EFFECTIVE SERVICES FOR ASTHMA- IMPACT OF NATIONAL GUIDELINES

    Sep 1, 2001, 00:00

  • PEE3- COSTS AND CONSEQUENCES OF OLOPATADINE 0.1 IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS

    Sep 1, 2001, 00:00

  • PWM4- PHARMACIST-INITIATED EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA

    Sep 1, 2001, 00:00
  • «
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178 (current)
  • 179
  • 180
  • »